MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/gutjnl-2024-334591

Медицинская библиотека · Gut · 2025

Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies.

Celsa Ciro, Pennisi Grazia, Tulone Adele, Ciancimino Giacinta, Vaccaro Marco, Infantino Giuseppe, Di Maria Gabriele, Pinato David J, Cabibbo Giuseppe, Enea Marco, Mantovani Alessandro, Tilg Herbert, Targher Giovanni, Cammà Calogero, Petta Salvatore

СтатьяМетаанализПеревод пока не подготовлен

Аннотация

BACKGROUND

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promising effects on liver histology in phase 2 trials enrolling patients with metabolic dysfunction-associated steatotic liver disease. However, the impact of GLP-1RAs on the long-term risk of major adverse liver-related outcomes (MALOs) remains uncertain.

OBJECTIVE

We performed a meta-analysis of observational cohort studies to quantify the magnitude and direction of the association between GLP-1RA use and MALOs in people with type 2 diabetes (T2D).

DESIGN

We systematically searched eligible cohort studies comparing GLP-1RA new users versus users of other glucose-lowering medications. The primary outcome was the cumulative incidence rates of MALOs. Secondary outcomes included hepatic decompensation events, hepatocellular carcinoma (HCC) and liver-related mortality. Random-effects models were used to calculate incidence rate ratios (IRRs).

RESULTS

11 retrospective cohort studies with aggregate data on 1 467 220 patients with T2D (647 903 GLP-1RA new users, 819 317 non-users) were included. GLP-1RA use was significantly associated with a lower risk of MALOs (IRR 0.71, 95% CI 0.57 to 0.88) and hepatic decompensation (IRR 0.70, 95% CI 0.52 to 0.94). Association with reduced risk of HCC was also observed (IRR 0.82, 95% CI 0.61 to 1.11). Compared with other antidiabetic medications, GLP-1RAs showed superior effectiveness versus SGLT2 inhibitors in preventing MALOs (IRR 0.93, 95% CI 0.87 to 0.99), versus DPP-4 inhibitors in preventing hepatic decompensation (IRR 0.74, 95% CI 0.66 to 0.83) and versus insulin therapy in preventing HCC (IRR 0.32, 95% CI 0.13 to 0.80).

CONCLUSIONS

GLP-1RA use is associated with a lower risk of liver-related complications and hepatic decompensation in people with T2D. These findings suggest a role of GLP-1RAs in preventing liver-related complications beyond their beneficial cardiometabolic effects.

Для цитирования: Celsa Ciro, Pennisi Grazia, Tulone Adele, Ciancimino Giacinta, Vaccaro Marco, Infantino Giuseppe, Di Maria Gabriele, Pinato David J, Cabibbo Giuseppe, Enea Marco, Mantovani Alessandro, Tilg Herbert, Targher Giovanni, Cammà Calogero, Petta Salvatore. Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies.. Gut. 2025. DOI: 10.1136/gutjnl-2024-334591.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.